Karyopharm Therapeutics reported Q2 revenue of $33.43 million, beating estimates thanks to strong sales of its cancer drug XPOVIO®. However, the company missed EPS expectations with a loss of $2.32 per share and faces financial challenges including negative debt-to-equity and cash flow ratios. Karyopharm is shifting focus to its Myelofibrosis program and advancing its Selinexor drug, maintaining its full-year revenue guidance of $130-$150 million.
Meta has agreed to an $18 billion legal settlement, which translates to about $1 billion per year—an amount negligible compared to its substantial revenue and earnings. The settlement resolves regulatory uncertainties, allowing Meta to focus on its c...
Genius Group, after selling its entire Bitcoin reserve to repay $8.5 million in debt, plans to rebuild its Bitcoin and AI treasuries to a combined $1.6 billion by fiscal year 2031. The company aims to grow total assets to $2 billion and will fund tre...
Veteran trader Peter Brandt revealed he remains long on Bitcoin even as the cryptocurrency struggles to break above the key resistance zone around $82,000. Bitcoin recently climbed above $80,000 but faced strong selling pressure, causing a pullback. ...
Grayscale's Zach Pandl highlights that the US Treasury's bond repurchases aim to ease pressure from soaring government debt, which recently surpassed $40 trillion. While these repurchases may reduce Treasury supply and stimulate the economy, they don...
GoMining introduced Instant Funds, a feature enabling eligible digital Bitcoin miner NFT holders to use their miners as collateral to borrow stablecoins like USDT or USDC without selling the miners. Users can access up to 30% of the miner's value wit...
